TRVI — Trevi Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1563880 ·
Last close
$18.08
Market Cap
$2.58B
52W High
$20.22
52W Low
$13.20
ADV30
1,962,076
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -20,509,000 | -17,797,000 | 330,518,000 | 54,302,000 | 9,012,000 |
| Mar 2026 | 0 | — | -14,912,000 | -13,192,000 | 179,606,000 | 19,412,000 | 7,479,000 |
| Dec 2025 | 0 | — | -10,220,000 | -8,316,000 | 193,439,000 | 18,914,000 | 10,195,000 |
| Sep 2025 | 0 | — | -13,916,000 | -11,802,000 | 199,356,000 | 56,869,000 | 9,568,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,629,000
Investing CF
$-176,619,000
Financing CF
$166,492,000
CapEx
$-233,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.34
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-360,793,000
Inventory
—
Receivables
—
ST Investments
$264,568,000
EBIT TTM
$-55,570,000
Pretax Income TTM
$-51,177,000
Interest Exp TTM
$0
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -49,328,000 | -42,759,000 | 193,439,000 | 10,195,000 | — | -42,089,000 |
| Dec 2024 | 0 | -51,524,000 | -47,911,000 | 110,900,000 | 11,256,000 | — | -38,256,000 |
| Dec 2023 | 0 | -33,923,000 | -29,065,000 | 89,403,000 | 6,856,000 | — | -31,710,000 |
| Dec 2022 | 0 | -29,907,000 | -29,152,000 | 123,015,000 | 15,556,000 | — | -28,175,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.00 · spot: $18.08 · call volume: 1,138 · put volume: 17Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | $2.56B | $7.17 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.54B | $25.72 | — |
| PHVS | Pharvaris N.V. | $2.62B | $37.31 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.62B | $45.11 | — |
| NKTR | NEKTAR THERAPEUTICS | $2.52B | $73.69 | — |
News headlines (Yahoo Finance, 1h cache)
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
2026-07-30 20:05 · Yahoo
Trevi Therapeutics Announces Upcoming June and July Event Schedule
2026-06-17 11:30 · Yahoo
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
2026-06-03 14:04 · Yahoo
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
2026-05-09 09:05 · Yahoo
Trevi Therapeutics Q1 Earnings Call Highlights
2026-05-06 04:08 · Yahoo
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-05 20:05 · Yahoo
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
2026-04-30 20:05 · Yahoo
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
2026-04-28 20:05 · Yahoo
Trevi Therapeutics to Participate in Upcoming May Events
2026-04-23 20:05 · Yahoo
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?
2026-04-22 13:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.